This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

90-day Medication Supply From Community Pharmacies Drives Better Adherence While Minimizing Wastage And Reducing Medicaid Costs, Walgreens Study Shows

A new Walgreens (NYSE: WAG) (Nasdaq: WAG) study examining the impact of 90-day medication refills at community pharmacies compared to 30-day refills for Medicaid patients found that across four therapeutic categories, patients with 90-day refills had greater medication adherence and greater persistency, nominal wastage and more cost savings. The study, titled Medication Days’ Supply, Adherence, Wastage, and Cost Among Chronic Patients in Medicaid, was published in the 2012 Vol. 2 (3) issue of Medicare & Medicaid Research Review.

The study’s release comes as states throughout the U.S. have aimed to contain Medicaid pharmacy costs by placing dispensing limits on medication days’ supply (most have a limit of 34 days), in an effort to limit medication wastage. The results demonstrate that wastage can be nominal across the 30-day and 90-day channels, and that three-month fills at community pharmacies have the potential to significantly improve outcomes and lower costs among Medicaid patients. Many of these patients include those with chronic conditions who often face major socioeconomic challenges affecting their ability to remain adherent to medication therapies. Notably, almost half (45 percent) of Medicaid beneficiaries have three or more chronic illnesses, and this population accounts for 75 percent of total Medicare costs. 1

Compared to 30-day refills, patients with 90-day refills at community pharmacies showed:
  • 20 percent higher adherence
  • 23 percent higher persistency
  • A projected savings of $13.95 per patient per year, after removing wastage costs and adjusting for the effects of age, gender and comorbidity

“Our 90-day refill program at our community pharmacies is an innovative health care solution that can help lower costs and improve patient outcomes, and another way in which Walgreens is advancing community pharmacy to help people get, stay and live well,” said Jeffrey Kang, MD, Walgreens senior vice president of pharmacy, health and wellness services and solutions. “At the time of our study, only 13 states gave Medicaid patients the option to receive a 90-day medication supply. However, with the growing popularity and adoption of 90-day refills at community pharmacies, more and more Medicaid patients have an opportunity to benefit from face-to-face pharmacist interaction and the personalized care our pharmacists provide. Both patients and the health care system could benefit from reexamination of these broad state dispensing limitations.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs